Indeed, in a prospective trial in China, patients with clinically diagnosed lung cancer who were unable to provide tissue for pathological diagnosis received icotinib based on the presence of a plasma EGFR mutation (without a pathological diagnosis) with a median progression-free survival (PFS) of 10.3 months [59]. The gene discussed is EGFR; the disease is lung carcinoma.